Skip to main
  1. Stocks
  2. HeartBeam
  3. Forecast
BEAT

HeartBeam (BEAT) Stock Forecast & Price Target

HeartBeam (BEAT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

HeartBeam is attractive fundamentally because management has sharpened its strategy toward the larger myocardial infarction detection opportunity, while retaining a differentiated 12-lead patch platform that combines continuous rhythm monitoring with on-demand 12-lead ECG synthesis for a roughly $2B reimbursed market. The company’s pilot ALIGN-ACS study enrolled 132 adults and showed higher specificity with comparable sensitivity versus a standard 12-lead ECG, and positive FDA interaction has made management believe MI clearance could arrive by year-end 2027. Financially, 3Q net cash used in operations fell to $2.6 million, 23% below 2Q26 and 18% below last year’s 3Q, with FY26 operating cash outflow guided to $12 million to $12.5 million as the company raises additional capital to fund through 2027.

Bears say

HeartBeam is facing a weak fundamental setup because management has effectively postponed a large-scale arrhythmia commercialization strategy and redirected scarce resources toward an MI indication that still lacks clear approval timing, creating a long and uncertain path to meaningful revenue. Although the company has active pilot studies and a pre-submission request to the FDA, the critical hurdles remain clinical validation, algorithm development, and regulatory execution, while near-term commercialization is expected to stay limited. Financially, 2Q26 net loss was $5.0 million, operating cash outflow was $3.3 million, cash stood at $8.7 million at the end of June 2026, and the company may need additional capital within 12 months, heightening dilution and going-concern risk.

HeartBeam (BEAT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HeartBeam and is not a guaranteed prediction by Public.com or investment advice.

HeartBeam (BEAT) Analyst Forecast & Price Prediction

Get the latest HeartBeam (BEAT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HeartBeam (BEAT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HeartBeam (BEAT) Forecast

Analysts have given HeartBeam (BEAT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, HeartBeam (BEAT) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HeartBeam (BEAT)


HeartBeam (BEAT) Analyst Forecast & Price Prediction

Get the latest HeartBeam (BEAT) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HeartBeam (BEAT)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BEAT stock data and trends